Details scant, but Verily-Sanofi’s $500M diabetes JV aims to change behavior – MedCity News https://t.co/U82x3xNfo8
— The Propell Group (@ThePropellGroup) September 17, 2016
#healthtech
Details scant, but Verily-Sanofi’s $500M diabetes JV aims to change behavior – MedCity News https://t.co/U82x3xNfo8
— The Propell Group (@ThePropellGroup) September 17, 2016
#healthtech